Colchicine

Denali’s registration statement on Form S-4 declared effective by the Securities and Exchange CommissionExtraordinary general meeting of Denali Capital Acquisition Corp. shareholders to approve the proposed business combination is scheduled to be held on September 3, 2025, at 9:00 a.m., Eastern TimePost-closing combined company will be renamed "Semnur Pharmaceuticals, Inc." in connection with the closing of the business combination PALO ALTO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX) , an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the registration statement on Form S-4 (the “Registration Statement”), related to the previously announced proposed business combination (the “Business Combination”) between Denali Capital Acquisition Corp. ("Denali") (OTCB: DNQAF), a special purpose acquisition company, and Semnur Pharmaceuticals, Inc. (“Semnur”), a majority-owned subsidiary of Scilex, has been declared effective by the U.S. Securities and Exchange Commission (the "SEC"). Denali will hold an extraordinary general meeting of shareholders (the “Meeting”) at 9:00 a.m., Eastern Time on Wednesday, September 3, 2025 to approve, among other things, the proposed Business Combination. Shareholders of record of Denali at the close of business on August 12, 2025 will be entitled to receive notice of, and to vote at, the Meeting. The Meeting will be held at the offices of US Tiger Securities, Inc. located at 437 Madison Avenue, 27th Floor, New York, New York 10022. The Business Combination is expected to close as soon as reasonably practicable after approval by Denali’s and Semnur’s shareholders and the satisfaction of other customary closing conditions as described in the Registration Statement. While the combined company has submitted an application to list the combined company’s common stock and warrants on The Nasdaq Stock Market LLC, approval has not yet been obtained and there can be no assurance that such listing application will be approved or that the combined company will meet the applicable listing standards. If the combined company is unable to obtain listing on a national securities exchange, the combined company’s securities will continue to trade on the OTC Markets following the Business Combination. For more information on Scilex Holding Company, refer to www.scilexholding.com For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com. For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com. For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com. https://www.facebook.com/scilex.pharm https://www.linkedin.com/company/scilex-holding-company/ info@scilexholding.com About Scilex Holding Company Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia. Scilex is headquartered in Palo Alto, California. About Semnur Pharmaceuticals, Inc. Semnur is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica. Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California About Denali Capital Acquisition Corp. Denali is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Important Information and Where to Find It This press release relates to a proposed transaction between Semnur and Denali and does not contain all the information that should be considered concerning the potential Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the potential Business Combination. The Registration Statement has been declared effective by the SEC, which includes the related proxy/prospectus of Denali (the “Proxy Statement/Prospectus”). Denali is mailing a definitive Proxy Statement/Prospectus and other relevant documents, including a proxy card, to the holders of record of Denali’s ordinary shares at the record date, August 12, 2025. This communication is not a substitute for the Registration Statement, the definitive Proxy Statement/Prospectus or any other document that Denali will send to its shareholders in connection with the Business Combination. Investors and security holders of Denali are urged to read these materials (including any amendments or supplements thereto) and any other relevant documents in connection with the transaction that Denali files with the SEC when, and if, they become available because they will contain important information about Denali, Semnur and the proposed transactions. The Proxy Statement/Prospectus and other relevant materials in connection with the transaction (when and if they become available), and any other documents filed by Denali with the SEC, may be obtained free of charge at the SEC’s website (www.sec.gov). The documents filed by Denali with the SEC also may be obtained free of charge upon written request to: Denali Capital Acquisition Corp.437 Madison Avenue, 27th FloorNew York, NY 10022 Participants in the Solicitation Denali and its directors and executive officers may be deemed participants in the solicitation of proxies from Denali’s shareholders with respect to the proposed Business Combination. Information about Denali’s directors and executive officers and a description of their interests in Denali is included in the Proxy Statement/Prospectus for the proposed transaction and is available at the SEC’s website (www.sec.gov). Semnur and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Denali in connection with the proposed Business Combination. Information about Semnur’s directors and executive officers and information regarding their interests in the proposed transaction is included in the Proxy Statement/Prospectus for the proposed transaction. Non-Solicitation This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Denali, the combined company or Semnur, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, the Business Combination between Semnur and Denali, the estimated or anticipated future results and benefits of the combined company following the Business Combination, including the likelihood and ability of the parties to successfully consummate the Business Combination, future opportunities for the combined company, and other statements that are not historical facts. These statements are based on the current expectations of management of the Company, Semnur and Denali and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company, Semnur and Denali. These statements are subject to a number of risks and uncertainties regarding the Company’s, Semnur’s and Denali’s businesses and the Business Combination, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the inability of the parties to consummate the Business Combination or the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement for the Business Combination; the outcome of any legal proceedings that may be instituted against the parties following the announcement of the Business Combination; the receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the Business Combination; the risk that the approval of the stockholders of Semnur or the shareholders of Denali for the potential transaction is not obtained; failure to realize the anticipated benefits of the Business Combination, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Semnur or Denali; the risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination; the ability of the combined company to develop and successfully market SP-102 or other products; the ability of the combined company to grow and manage growth profitably and retain its key employees; the amount of redemption requests made by Denali’s shareholders; the inability to obtain or maintain the listing or trading of the post-acquisition company’s securities on Nasdaq or OTC Markets, as applicable, following the Business Combination; and costs related to the Business Combination. There may be additional risks that Semnur and the Company presently do not know or that Semnur or the Company currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Semnur’s, the Company’s and Denali’s expectations, plans or forecasts of future events and views as of the date of the communication. Semnur and the Company anticipate that subsequent events and developments will cause such assessments to change. However, while Semnur and the Company may elect to update these forward-looking statements at some point in the future, each of Semnur and the Company specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Semnur’s or the Company’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements. Contacts: Investors and MediaScilex Holding Company 960 San Antonio RoadPalo Alto, CA 94303Office: (650) 516-4310 Email: investorrelations@scilexholding.com Website: www.scilexholding.com SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company. ELYXYB® is a registered trademark owned by Scilex Holding Company. Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc. All other trademarks are the property of their respective owners. © 2025 Scilex Holding Company All Rights Reserved.

每一个不曾起舞的日子 都是对生命的辜负 …… 二战时期，战火连天，疾病肆虐 大面积的感染，难以控制的疟疾 疾病，成了比战争更可怕的恶魔 在很多地方，抗疟疾药，成了救命的东西 而大名鼎鼎的奎宁（俗称金鸡纳霜），是当时唯一能治疗疟疾的药物 可战争期间，天然的奎宁供不应求 眼看着数百万人正深陷疟疾的威胁之中 这时候，他站了出来，成了大家的保护神 金鸡纳 维生素B12，最后一个被发现的B族维生素 最复杂的天然物质之一，有机合成界的珠穆朗玛峰 这种人体必须的维生素，却只有微生物才能生产 提取工艺复杂，产量低，价格高昂，供不应求 可却始终没有人能合成出那么复杂的物质 又是他，带领着100多位化学家一起攻关 攀登上了这座有机合成界令人望而生畏的高峰 他是有机合成界的“蓝精灵” 是因为实在偏科得太严重而被MIT退学的学生 更是有史以来最伟大的化学家之一 他是有机合成之父——罗伯特·伯恩斯·伍德沃德（Robert Burns Woodward） … 伍德沃德出生在美国马萨诸塞州的波士顿 他从小就特别喜欢蓝色，还特别喜欢化学 当他看到要用来和生石灰混合来消毒的硫酸铜溶液的时候 那透明澄澈的蓝，那纯净美好的蓝，他简直被迷住了 刚上小学，当同龄的小伙伴只想着放学去哪里玩的时候 他就买了各种瓶瓶罐罐，在自家的地下室里捣鼓起了他的“化学实验室” 在他上高中之前，就已经把学校里通用的有机化学实验教材大部分的实验做完了 实验水平秒杀一众高中的师兄师姐 更重要的是，他收集到了几十种迷人的蓝色溶液、蓝色粉末… 德国强大的科学研究实力让年幼的伍德沃德心驰神往 可才11岁的他，也不太可能去到德国学些什么东西 不过嘛，德国有驻波士顿的领事馆 小小年纪的伍德沃德找到了领事馆的总领事 通过总领事的帮助，他拿到了只发表在德国期刊上的最顶级研究论文 当然，也学到了很多前沿的化学知识，做了更多的实验，拿到了更多的“化学蓝” 德国驻华盛顿大使馆 1933年，素有“神童”之称的伍德沃德在16岁的时候就考入了美国最出名的理工类大学——MIT（麻省理工学院） 当时的班上，除了他，都是20岁上下的大哥哥大姐姐 而年纪最小的他，从入学起就被寄予了厚望 可是伍德沃德实在是太喜欢化学了 他将自己所有的精力都投入了化学 以至于1年之后，除了化学，他所有的科目统统挂了科 MIT竟然也不接收偏科生 在MIT的校史上何曾出现过成绩如此糟糕的学生 学校二话不说，就把伍德沃德开除了 这可急坏了MIT的化学系的各位教授们 伍德沃德可是他们见过的最有化学天赋的学生 教授们聚在一起讨论了半天，给校长写了一封联名信，希望能留下这个天赋异禀的学生 第二年，18岁的伍德沃德重新回到了MIT的校园 这一回，学校为了培养他，给他开了小灶，专门安排了许多课程 伍德沃德也没有辜负大家的期望，1年的时间，他拿到了学士学位 再一年的时间，他又拿到了博士学位 当他20岁那年通过了博士论文答辩，拿到博士学位证的时候 他的很多同学（第一次入读MIT时候的同学），甚至连学士学位都还没拿到 普通人要读6年才能拿到的博士学位，他用1年就拿到了 这在MIT也是绝无仅有的 博士毕业后的伍德沃德，在哈佛大学执教 于是，哈佛大学出现了这样一幕 一位20岁的讲师在讲台上给22、23岁的学生们上课 伍德沃德博士毕业不久后，第二次世界大战拉开了序幕 在日军的占领下，来自东南亚国家的奎宁变得更为稀缺 战争，让疟疾的传播变得更为迅速与广泛 奎宁的供不应求，将数百万人的性命暴露在疟疾的威胁下 一场随时可能爆发的疟疾狂潮让所有的人都忧心不已 罹患疟疾的儿童 这时，伍德沃德做出了一个惊人的决定，人工合成奎宁 听到他要合成奎宁，他的同事们都惊呆了 纵然他是个“神童”，也不能说出什么大言不惭的话吧 上世纪40年代，有机化学总体上还是一门实验学科 当时的人们普遍认为，像奎宁这样的复杂分子，是不可能被合成出来的 奎宁结构式 伍德沃德才不在乎同事们的嘲笑 他来到了实验室里，一心思索着要如何合成奎宁 苦苦想了好几天，伍德沃德仍然一筹莫展 心情烦躁不堪的他一气之下把家里所有的东西都换成了蓝色 墙壁、窗帘、床单、桌子…宁静而平和的蓝色，似乎真的让他静下了心 他躺在蓝色的床上，看着蓝色的天花板，进入了梦乡 蓝精灵般的伍德沃德 或许是他钟爱的蓝色真的给了他灵感 当伍德沃德再一次回到实验室的时候 他照着自己的想法探索了一阵 那被说成不可能能人工合成的奎宁出现在了他的眼前 伍德沃德在实验室合成奎宁 55道复杂的程序，繁琐的制备方法 纵然当时的合成工艺无法进行奎宁的工业化生产 但不管怎么说，这是化学合成的一个里程碑 紧接着，伍德沃德的灵感一个接着一个蹦出来 胆固醇、可的松、叶绿素、秋水仙碱… 一大堆之前只能从天然物质中提取的化合物在他的实验室里诞生 他告诉人们，只要仔细运用物理有机化学的原理，有精细的策划，天然产物是可以通过人工的方法合成出来的 伍德沃德与叶绿素（结构式） 伍德沃德的工作更像是艺术 从那以后，合成的化学家们总是力求实用与美的结合 那个时代，被人们称为“伍德沃德时代” 他还有着非同寻常的对化学的直觉 上世纪60年代的时候，土霉素的结构式鉴定是业界的难题 众多化学家们都投入到了其结构式的研究中 各种研究数据繁多而杂乱，令人毫无头绪 伍德沃德拿了张卡片，将数据一个个罗列出来 静思良久，竟然在卡片上将土霉素的结构式一处不错的写了下来 惊呆了他的同事、朋友和众多的化学家们 土霉素结构式 1965年，凭借着在合成化学上的成就 陪跑了131次（获得过131次诺贝尔奖提名）的伍德沃德终于上位 拿到了当年的诺贝尔化学奖 就在他去领奖的路上，看着车外蓝色的天空 头孢霉素的合成方法一点点在他的脑海里拼凑了出来 于是，他硬生生的将获奖感言变成了制备头孢霉素的学术讲座 他说他已经为头孢霉素设计了切实可行的合成方法，颁奖后，很快就能将它做出来 台下的观众，台上的颁奖嘉宾，都被他说得一愣一愣的 拿到了诺贝尔奖的伍德沃德并没有就此停止自己的研究 而是向着更为艰巨复杂的化学合成方向前进 这一次，他的目标是化学合成界的珠穆朗玛峰——维生素B12 现在，维生素B12不过是药店卖的几块钱一瓶的小药片 可是在几十年前，当我们还不能合成维生素B12的时候 这种极为重要的药物，只能从动物的肝脏中提取，价格昂贵，供不应求 自然界中的维生素B12都是微生物合成的，高等动植物不能制造维生素B12。自然界中的维生素B12主要是通过草食动物的瘤胃和结肠中的细菌合成的的，因此，其膳食来源主要为动物性食品，其中动物内脏、肉类、蛋类是维生素B12的丰富来源。 维生素B12的主要生理功能是参与制造骨髓红细胞，防止恶性贫血；防止大脑神经受到破坏。 维生素B12的缺乏，会导致神经系统的损伤与恶性的贫血 精神抑郁、睡眠质量低下、记忆力下降… 对于维生素B12缺乏的人群来说，日子过得异常艰难 经过研究，伍德沃德发现，维生素B12有181个原子 这些原子在空间呈魔毡状分布，性质极为脆弱 强酸、强碱、高温，都会让维生素B12分解 这给维生素B12的合成造成了极大的困难 要想按照之前的方法，一步步的合成维生素B12，基本是天方夜谭 伍德沃德显然也知道这一点 只有创立新的合成技术，才可能攀上这座高峰 维生素B12结构式 伍德沃德觉得，自己需要再多一些的灵感 而他的灵感来源…对，就是“化学蓝” 他花了大价钱买了一辆蓝色的车，里里外外都涂成了蓝色 甚至还把自己的停车位也刷成了蓝色 他坐在车里，被蓝色包裹着，感觉好极了 这时候，灵感真的来找他了 既然不能一步步合成，那分开来，一部分一部分的合成，再拼起来，这不就行了吗 而这种方法，正是如今通用的合成复杂有机化合物的方法 有了初步的想法，还要设计合成的路线 毕竟维生素B12那么复杂，不是说一说就能合成的东西 近千个复杂的有机合成实验，11年的时间 伍德沃德终于完成了维生素B12的合成工作 维生素B12的全合成 在合成维生素B12的过程中 他还与他的合作者霍夫曼一起，提出了分子轨道对称守恒原理 这个理论，简单直观地揭示了许多有机化学反应的过程 而这个理论的创立，使霍夫曼、福井谦一同获得了1981年的诺贝尔化学家 若非伍德沃德那时候已经不在人世 他会成为为数不多的获得过两次诺贝尔奖的人 有机合成，需要长时间的守护、观察和记录 那时，伍德沃德每天的休息时间不超过4个小时 而除了睡觉和吃饭，他所有的时间都在实验室里工作 他是个出了名的工作狂魔 一辈子的时间都献给了化学研究 过于忙碌的生活让他无暇顾及自己的家庭 即便他着实有着不低的颜值，可他的3段婚姻都无疾而终 500多名学生，200多名博士与博士后 他的学生已经遍布世界各地 多个国家的院士，各种公司的技术指导 他身上的荣誉更是数不胜数 1979年，伍德沃德积劳成疾，心脏病突发而与世长辞，终年62岁 在他辞世前，他仍然念念不忘他的有机合成工作，记挂着他那还没合成完的赤霉素 为了完成他的心愿，他曾经的学生义无反顾的接替了他的研究组，完成了赤霉素的合成 正如伍德沃德所说"合成，是一门艺术" 艺术需要被传承和创新 声明: 本文转自：SME科技故事，非原创内容，版权和内容解释权归原作者所有。在这里仅供交流使用，如涉及版权问题，请联系删除。